Evidence map›Paper›PMID 32878888›Full record

ArticleJournal of virology2020

Ionic Strength-Dependent, Reversible Pleomorphism of Recombinant Newcastle Disease Virus.

Benjamin S Rush, Matieyendou Didier Djagbare, Jeffrey A Speir, Gautam Sanyal

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Benjamin S RushAstraZeneca Biopharmaceuticals, Gaithersburg, Maryland, USA.
Matieyendou Didier DjagbareAstraZeneca Biopharmaceuticals, Gaithersburg, Maryland, USA.
Jeffrey A SpeirNanoimaging Services, San Diego, California, USA.
Gautam SanyalAstraZeneca Biopharmaceuticals, Gaithersburg, Maryland, USA gautam.sanyal@vaccineanalytics.org.
AstraZeneca (United States) · USNanoImaging Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A genetically modified, recombinant form of Newcastle disease virus (rNDV) undergoes ionic strength-dependent changes in morphology, as observed by cryo-electron microscopy (cEM). In hypotonic solutions with ionic strengths ranging from < 0.01 to 0.02 M, rNDV virions are spherical or predominantly spherical. In isotonic and hypertonic solutions, rNDV displays pleomorphism and contains a mixed population of spherical and elongated particles, indicating that a change from spherical to elongated shape is induced with increasing salt concentration. This ionic strength-dependent transition is largely reversible, as determined by cEM. Concomitantly, we measured infectious titers of these same rNDV samples at different ionic strengths using a fluorescent focus assay (FFA). The infectivity of oncolytic rNDV was found to be independent of ionic strength, ranging from 0.01 M to approximately 0.5 M. These structural and functional observations, in combination, suggest that infectivity (and, by inference, oncolytic activity) of rNDV virions is fully maintained in their pleomorphic forms.

Indexed as

AnimalsChickensCryoelectron MicroscopyHumansNewcastle DiseaseNewcastle disease virusOncolytic VirusesOsmolar Concentrationcryo-electron microscopyfluorescent focus assaygenetically modifiedinfectious titerionic strengthNewcastle disease virusoncolytic activitypleomorphismrecombinantrecombinant Newcastle disease virusreversiblevirion morphology

Identifiers

PMID32878888
PMCPMC7592199
OpenAlexW3082830567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.